Norway’s Targovax has added to its senior team with the appointment of two executives from Algeta.
Anna-Kirsti Aksnes joins the cancer immunotherapy specialist as VP clinical development and Tina Madsen joins as VP quality assurance.
Aksnes was most recently VP clinical research at Algeta, which was taken over by pharma giant Bayer in 2014. In her role she helped lead strategic, scientific, clinical development and medical communications for the company.
Madsen joins as VP quality assurance, joining from the position of director of product quality assurance. She has over 20 years of experience in the life sciences industry.
Commenting on the appointments, Targovax’s CEO Gunnar Gardemyr said: “I am pleased to welcome Anne-Kirst and Tina to our team. We look forward to the insight and wealth of experience that they bring to Targovax.”